UPDATED: Bluebird says it has more good news for its gene therapy safety, but a pricing disagreement in Germany will spur layoffs
Following two safety scares back in February regarding its sickle-cell program, bluebird bio’s gene therapy appears to be in the clear.
Execs from the Cambridge, MA-based biotech provided another update on LentiGlobin safety concerns Tuesday morning, this time regarding a patient who was thought to have developed a case of myelodysplastic syndrome. After further analyses and testing, investigators have revised the diagnosis to transfusion-dependent anemia and ruled that it is not an incident of the blood cancer.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 105,400+ biopharma pros reading Endpoints daily — and it's free.